Skip to main content
Top
Published in: Journal of Cancer Survivorship 1/2014

01-03-2014

Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada

Authors: Claire de Oliveira, Karen E. Bremner, Andy Ni, Shabbir M. H. Alibhai, Audrey Laporte, Murray D. Krahn

Published in: Journal of Cancer Survivorship | Issue 1/2014

Login to get access

Abstract

Purpose

Time and out-of-pocket (OOP) costs can represent a substantial burden for cancer patients but have not been described for long-term cancer survivors. We estimated these costs, their predictors, and their relationship to financial income, among a cohort of long-term prostate cancer (PC) survivors.

Methods

A population-based, community-dwelling, geographically diverse sample of long-term (2–13 years) PC survivors in Ontario, Canada, was identified from the Ontario Cancer Registry and contacted through their referring physicians. We obtained data on demographics, health care resource use, and OOP costs through mailed questionnaires and conducted chart reviews to obtain clinical data. We compared mean annual time and OOP costs (2006 Canadian dollars) across clinical and sociodemographic characteristics and examined the association between costs and four groups of predictors (patient, disease, system, symptom) using two-part regression models.

Results

Patients' (N = 585) mean age was 73 years; 77 % were retired, and 42 % reported total annual incomes less than $40,000. Overall, mean time costs were $838/year and mean OOP costs were $200/year. Although generally low, total costs represented approximately 10 % of income for lower income patients. No demographic variables were associated with costs. Radical prostatectomy, younger age, poor urinary function, current androgen deprivation therapy, and recent diagnosis were significantly associated with increased likelihood of incurring any costs, but only urinary function significantly affected total amount.

Conclusions

Time and OOP costs are modest for most long-term PC survivors but can represent a substantial burden for lower income patients. Even several years after diagnosis, PC-specific treatments and treatment-related dysfunction are associated with increased costs.

Implications for Cancer Survivors

Time and out-of-pocket costs are generally manageable for long-term PC survivors but can be a significant burden mainly for lower income patients. The effects of PC-specific, treatment-related dysfunctions on quality of life can also represent sources of expense for patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Longo CJ, Fitch M, Deber RB, Williams AP. Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer. 2006;14:1077–85.CrossRefPubMed Longo CJ, Fitch M, Deber RB, Williams AP. Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer. 2006;14:1077–85.CrossRefPubMed
2.
go back to reference Longo CJ, Deber R, Fitch M, Williams P, DeSouza D. An examination of cancer patients' monthly “out-of-pocket” costs in Ontario. Eur J Cancer Care. 2007;16:500–7.CrossRef Longo CJ, Deber R, Fitch M, Williams P, DeSouza D. An examination of cancer patients' monthly “out-of-pocket” costs in Ontario. Eur J Cancer Care. 2007;16:500–7.CrossRef
3.
go back to reference Federico CA, Hsu PC, Krajden M, Yoshida EM, Bremner KE, Weiss AA, et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int. 2012;32(5):815–25.CrossRefPubMed Federico CA, Hsu PC, Krajden M, Yoshida EM, Bremner KE, Weiss AA, et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int. 2012;32(5):815–25.CrossRefPubMed
4.
go back to reference Mathews M, West R, Buehler S. How important are out-of-pocket costs to rural patients' cancer care decisions? Can J Rural Med. 2009;14(2):54–60.PubMed Mathews M, West R, Buehler S. How important are out-of-pocket costs to rural patients' cancer care decisions? Can J Rural Med. 2009;14(2):54–60.PubMed
5.
go back to reference Langa KM, Fendrick AM, Chernew ME, Kabeto MU, Paisley KL, Hayman JA. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004;7(2):186–94.CrossRefPubMed Langa KM, Fendrick AM, Chernew ME, Kabeto MU, Paisley KL, Hayman JA. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004;7(2):186–94.CrossRefPubMed
6.
go back to reference Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43(7):640–8.CrossRefPubMed Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43(7):640–8.CrossRefPubMed
7.
go back to reference Yabroff KR, Kim Y. Time costs associated with informal care giving for cancer survivors. Cancer. 2009;115(18 Suppl):4362–73.CrossRefPubMed Yabroff KR, Kim Y. Time costs associated with informal care giving for cancer survivors. Cancer. 2009;115(18 Suppl):4362–73.CrossRefPubMed
8.
go back to reference Huang J, Zhou S, Groome P, Tyldesley S, Zhang-Solomans J, Mackillop WJ. Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol. 2001;19(1):137–44.PubMed Huang J, Zhou S, Groome P, Tyldesley S, Zhang-Solomans J, Mackillop WJ. Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol. 2001;19(1):137–44.PubMed
9.
go back to reference Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed
10.
go back to reference Krahn MD, Zagorski B, Laporte A, Alibhai SMH, Bremner KE, Tomlinson G, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. Br J Urol Int. 2010;105(3):338–40.CrossRef Krahn MD, Zagorski B, Laporte A, Alibhai SMH, Bremner KE, Tomlinson G, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. Br J Urol Int. 2010;105(3):338–40.CrossRef
11.
go back to reference Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data. Content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8, Supplement):IV-3–18. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data. Content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8, Supplement):IV-3–18.
12.
go back to reference Hall S, Schulze K, Groome P, McKillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario cancer registry. J Clin Epidemiol. 2006;59:67–76.CrossRefPubMed Hall S, Schulze K, Groome P, McKillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario cancer registry. J Clin Epidemiol. 2006;59:67–76.CrossRefPubMed
13.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.CrossRefPubMed
14.
go back to reference Litwin MS, Hays RD, Fink A, et al. The UCLA prostate cancer index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.CrossRefPubMed Litwin MS, Hays RD, Fink A, et al. The UCLA prostate cancer index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.CrossRefPubMed
15.
go back to reference Van Buuren S, Oudshoorn CGM. Flexible multivariate imputation by MICE. Leiden: TNO Preventie en Gezondheid, TNO/VGZ/PG 99.054, 1999. Van Buuren S, Oudshoorn CGM. Flexible multivariate imputation by MICE. Leiden: TNO Preventie en Gezondheid, TNO/VGZ/PG 99.054, 1999.
16.
go back to reference Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Br Med J. 2009;338:b2393.CrossRef Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Br Med J. 2009;338:b2393.CrossRef
17.
go back to reference Jones AM, Rice N, Bago d’Uva T, Balia S. Applied health economics. London: Routledge; 2007. Jones AM, Rice N, Bago d’Uva T, Balia S. Applied health economics. London: Routledge; 2007.
18.
go back to reference R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria.
19.
go back to reference SAS Inc. SAS 9.1.3 for Windows. Cary, N.C., USA. SAS Inc. SAS 9.1.3 for Windows. Cary, N.C., USA.
20.
go back to reference Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qualily Life Res. 2007;16:509–22.CrossRef Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qualily Life Res. 2007;16:509–22.CrossRef
21.
go back to reference Krahn MD, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41:153–64.CrossRefPubMed Krahn MD, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41:153–64.CrossRefPubMed
22.
go back to reference Pisu M, Azuero A, McNees P, Burkhardt J, Benz R, Meneses K. The out of pocket cost of breast cancer survivors: a review. J Cancer Survivorship. 2010;4(3):202–9.CrossRef Pisu M, Azuero A, McNees P, Burkhardt J, Benz R, Meneses K. The out of pocket cost of breast cancer survivors: a review. J Cancer Survivorship. 2010;4(3):202–9.CrossRef
23.
go back to reference Jayadevappa R, Schwartz JS, Chhatre S, Gallo JJ, Wein AJ, Malkowicz SB. The burden of out-of-pocket and indirect costs of prostate cancer. Prostate. 2010;70(11):1255–64.CrossRefPubMed Jayadevappa R, Schwartz JS, Chhatre S, Gallo JJ, Wein AJ, Malkowicz SB. The burden of out-of-pocket and indirect costs of prostate cancer. Prostate. 2010;70(11):1255–64.CrossRefPubMed
24.
go back to reference Taylor AKL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30(22):2768–75.PubMedCentralCrossRefPubMed Taylor AKL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30(22):2768–75.PubMedCentralCrossRefPubMed
25.
go back to reference Krahn MD, Bremner KE, Alibhai SMH, Ni A, Tomlinson G, Laporte A, Naglie G. A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. Quality of Life Research. 2013. doi:10.1177/0272989X13493970. Krahn MD, Bremner KE, Alibhai SMH, Ni A, Tomlinson G, Laporte A, Naglie G. A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. Quality of Life Research. 2013. doi:10.​1177/​0272989X13493970​.
26.
go back to reference Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96(17):1322–30.CrossRefPubMed Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96(17):1322–30.CrossRefPubMed
27.
go back to reference Mickevičienė A, Vanagas G, Ulys A, Jievaltas M, Smailytė G, Padaiga Ž. Factors affecting health-related quality of life in prostate cancer patients. Scan J Urol Nephrol. 2012;46(3):180–7.CrossRef Mickevičienė A, Vanagas G, Ulys A, Jievaltas M, Smailytė G, Padaiga Ž. Factors affecting health-related quality of life in prostate cancer patients. Scan J Urol Nephrol. 2012;46(3):180–7.CrossRef
28.
go back to reference Lauzier S, Maunsell E, Drolet M, Coyle D, Hébert-Croteau N. Validity of information obtained from a method for estimating cancer costs from the perspective of patients and caregivers. Qual Life Res. 2010;19(2):177–89.CrossRefPubMed Lauzier S, Maunsell E, Drolet M, Coyle D, Hébert-Croteau N. Validity of information obtained from a method for estimating cancer costs from the perspective of patients and caregivers. Qual Life Res. 2010;19(2):177–89.CrossRefPubMed
Metadata
Title
Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada
Authors
Claire de Oliveira
Karen E. Bremner
Andy Ni
Shabbir M. H. Alibhai
Audrey Laporte
Murray D. Krahn
Publication date
01-03-2014
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 1/2014
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-013-0305-7

Other articles of this Issue 1/2014

Journal of Cancer Survivorship 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine